Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Descourt, R.; Pérol, Maurice; Rousseau-Bussac, G.; Planchard, David; Mennecier, B.; Wislez, Marie; Cortot, A.; Guisier, Florian; Galland, Loïck; Dô, Pascal; Schött, Roland; Dansin, Éric; Arrondeau, Jennifer; Auliac, J.B.; Chouaïd, C.

doi:10.1016/j.lungcan.2019.08.010

Cited by 20 publications

(14 citation statements)

References 23 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The UVEA-Brig study, a retrospective analysis of patients with ALK + metastatic NSCLC who were treated with brigatinib in an EAP in four European countries, has provided real-world data indicating that brigatinib has substantial activity and is generally well tolerated when used in daily clinical practice to treat patients with ALK + metastatic NSCLC who had been considerably more heavily pretreated than those enrolled into clinical trials [14,27,28,31]; in addition, patients with poorer ECOG performance status were enrolled, although the incidence of brain metastases was similar to that in the ALTA trial of second-line brigatinib [27]. The study adds to evidence from previous studies indicating the efficacy and safety of brigatinib in real-world clinical practice [32][33][34].…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

et al. 2021

View full text Add to dashboard Cite

Background:The next-generation ALK inhibitor brigatinib is approved for use in patients with ALK inhibitornaïve ALK-positive advanced NSCLC and in patients previously treated with crizotinib. A phase II trial showed that brigatinib is active in patients with ALK-positive metastatic NSCLC (mNSCLC) who had progressed on prior crizotinib (response rate 56 %, median PFS 16.7 months, median OS 34.1 months). We report final data from the UVEA-Brig study of brigatinib in ALK inhibitor-pretreated ALK-positive mNSCLC in clinical practice. Methods: UVEA-Brig was a retrospective chart review of patients treated with brigatinib in Italy, Norway, Spain and the UK in an expanded access program. Adults with ALK-positive mNSCLC, including those with brain lesions, resistant to or intolerant of ≥1 prior ALK inhibitor and ECOG performance status ≤3 were eligible. Patients received brigatinib 180 mg once daily with a 7-day lead-in at 90 mg. The objectives were to describe patient characteristics, clinical disease presentation, treatment regimens used and clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 79%

“…The BRIGALK study analyzed 184 patients with ALK + advanced NSCLC included in the French EAP for brigatinib, who had previously been treated with at least one ALK TKI; median PFS was 4.8 (3.8-5.6) months [33]. In the UVEA-Brig study, median PFS was 11.3 (95 % CI:8.6-12.9) months overall.…”

Section: Discussionmentioning

confidence: 99%

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pulmonary toxicity is rare but potentially a severe event that can occur early after treatment initiation. The first real-world data have been published in the last year, confirming the promising results from the pivotal studies [ 49 – 51 ].…”

Section: Current Anaplastic Lymphoma Kinase (Alk) Tyrosine Kinase Inhibitorsmentioning

confidence: 66%

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer

Kauffmann-Guerrero

Kahnert

Huber

2020

Drugs

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases and is the leading cause of cancer-related deaths. Most NSCLC patients are diagnosed with advanced disease and require systemic treatment. Despite emerging advances in chemotherapy and immunotherapy, the prognosis of stage IV patients remains poor. However, the discovery of oncogenic driver mutations including mutations in the epidermal growth factor receptor (EGFR), the anaplastic lymphoma kinase (ALK) and others, characterize a subset of patients with the opportunity of targeted therapies. Fusions between the ALK and echinoderm microtubule-associated protein-like 4 (EML4) are present in ∼ 3–5% of patients with NSCLC. Several first-, second-, and third-generation ALK tyrosine kinase inhibitors (TKIs) have been developed in the last decade and have tremendously changed treatment options and outcomes of ALK-positive NSCLC patients. With increasing treatment options, treatment sequence decisions have become more and more complex. ALK-mutations, fusion variants, or activation of by-pass pathways result in treatment resistance during the course of treatment in nearly all patients. Mutation-guided treatment sequencing can lead to better outcomes, and re-biopsy or liquid-biopsy should be performed whenever possible in case of disease progression in ALK-rearranged patients. In the future, combinational treatment of ALK TKIs with other pathway-inhibitors might further improve patients’ treatment options and outcomes. Here, we review the data for currently available ALK TKIs, discuss approaches of treatment sequencing, and give an outlook on emerging developments.

show abstract

“…Unlike other clinical trials in NSCLC patients, phase III randomized controlled trials in ALK-rearranged NSCLC patients included up to 350 patients (12,13). In most recent retrospective clinical practice studies, the number of patients evaluated was around 100 (14)(15)(16)(17)(18)(19)(20). Several studies on tumor markers in ALK-rearranged NSCLC patients have been reported (21)(22)(23)(24).…”

Section: Discussionmentioning

confidence: 99%

Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis

Numata

Endo

Yanai

et al. 2020

In Vivo

View full text Add to dashboard Cite

Aim: To clarify the correlation between serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients. Patients and Methods: CEA and CYFRA levels in 131 ALK-rearranged NSCLC patients were determined using fluorescence in situ hybridization (FISH), real time-reverse transcription polymerase chain reaction, and immunohistochemistry, using biopsy specimens, cytology specimens, and plasma specimens. Cutoff value of each marker was determined as 10 ng/ml. Results: In logistic regression analysis, higher levels of both markers had a positive relationship with bone metastases, and higher levels of CYFRA was relevant to liver metastases, and multiple-organ metastases. However, these markers were not proven to be poor prognostic factors in Cox's proportional model analysis. Conclusion: Elevated serum CEA and CYFRA levels seem to provide useful clinical information about presence of bone and liver metastasis and multiple-organ metastases, although they were not a powerful indicator of prognosis. These two markers may suggest the extension of metastasis and would be helpful in considering treatment options. Carcinoembryonic antigen (CEA) has been widely used in clinical practice as a serum tumor marker for non-small cell lung cancer (NSCLC) patients (1). Cytokeratin 19 fragment (CYFRA) is also one of the representative serum tumor markers used for detection of NSCLC patients in clinical practice (1). CEA is a glycoprotein and CYFRA is a soluble 2095 This article is freely accessible online.

show abstract

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Cited by 20 publications

References 23 publications

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer

Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer

Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis

Contact Info

Product

Resources

About